Jiun-I Lai

Dr. Jiun-I Lai


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2017 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SCShih‐Chieh Chang
Shih‐Chieh Chang
YLYi‐Chun Lai
Yi‐Chun Lai
YCYen‐Chung Chen
Yen‐Chung Chen
NWNai‐Kuan Wang
Nai‐Kuan Wang
WWWei‐Shu Wang
Wei‐Shu Wang
JLJiun-I Lai
Jiun-I Lai

1 January 2013 in Academic Radiology
Verified
Journal Article
Closed access
YCYu-Hui Chiu
Yu-Hui Chiu
JCJen-Dar Chen
Jen-Dar Chen
SWShih-Hao Wang
Shih-Hao Wang
CTChui-Mei Tiu
Chui-Mei Tiu
CHChorng-Kuang How
Chorng-Kuang How
RCRay-Jade Chen
Ray-Jade Chen

23 November 2023 in The Oncologist
Verified
Journal Article
Open access
PDF file
JLJiun-I Lai
Jiun-I Lai
TKTing-Hao Kuo
Ting-Hao Kuo
KHKuan-Jung Huang
Kuan-Jung Huang
LCLaura Min Xuan Chai
Laura Min Xuan Chai
MLMei-Hsuan Lee
Mei-Hsuan Lee
TCTa-Chung Chao
Ta-Chung Chao
Background: CDK4/6 inhibitors (CDK4/6i) have shown great efficacy in prolonging progression-free survival and is the current standard of care for hormone positive (HR(+)) metastatic breast cancer (mBC). Despite well tolerability and ease of use, the most common side effect of CDK4/6i is myelosuppression, with neutropenia the most prevalent adverse effect. Studies show that the prevalence and severity of neutropenia are more marked in Asian patients, although details remain obscure. Methods: In this study, we retrospectively analyzed 105 Taiwanese patients who received palbociclib for HR(+) HER2(−) mBC at the Taipei Veterans General Hospital. To investigate a possible genetic association for high prevalence of neutropenia, we queried the Taiwan Biobank with publicly available germline databases (ALFA, gnomAD, ExAC, 1000 Genomes project, HapMap), for the allele frequencies of 4 neutropenia-related SNPs (ABCB1_rs1045642, ABCB1_rs1128503, ERCC1_rs3212986, ERCC1_rs11615) and compared between different ethnicities. In addition, one of the patients was a long-term patient with peritoneal dialysis. We quantified the levels of palbociclib in her serum and peritoneal fluid by liquid chromatography-mass spectrometry (LC-MS). Results: Interestingly, in our cohort, early neutropenia nadir (occurred within 56 days of start) was associated with worse treatment outcome, while occurrence of grade 3/4 neutropenia was associated with better outcome. We observed an extremely high incidence of neutropenia (96.2% any grade, 70.4% grade 3/4). In the analyzed germline databases, we discovered a higher SNP frequency of the T allele in ABCB1_rs1128503, a lower frequency of T allele in ABCB1_rs1045642, and a higher SNP frequency of G allele in ERCC1_rs11615. We observed that palbociclib levels in peritoneal dialysate ranged from around 20-50 ppb, and serum levels reached 100-110 ppb during drug administration and decreased to <10 ppb during discontinuation. Conclusion: Our retrospective analysis of real world palbociclib use reveals an association with grade 3/4 neutropenia with better outcome and early neutropenia nadir with worse outcome. Our findings of Asian specific SNPs support a predisposition toward profound and prevalent neutropenia in Asian patients under CDK4/6i. We also report the first pharmacokinetics analysis on a patient with peritoneal dialysis receiving CDK4/6i. In summary, our study provides novel clinical and genotypic insights into CDK4/6i associated neutropenia.

18 May 2023 in Experimental Cell Research
Verified
Journal Article
Open access
LTLing-Ming Tseng
Ling-Ming Tseng
KLKa-Yi Lau
Ka-Yi Lau
JCJi-Lin Chen
Ji-Lin Chen
PCPei-Yi Chu
Pei-Yi Chu
Tzu-Ting HuangTzu-Ting Huang
Tzu-Ting Huang
CLChun-Yu Liu
Chun-Yu Liu
Damage associated molecular patterns (DAMPs), including calreticulin (CRT) exposure, high-mobility group box 1 protein (HMGB1) elevation, and ATP release, characterize immunogenic cell death (ICD) and may play a role in cancer immunotherapy. Triple negative breast cancer (TNBC) is an immunogenic subtype of breast cancer with higher lymphocyte infiltration. Here, we found that regorafenib, a multi-target angiokinase inhibitor previously known to suppress STAT3 signaling, induced DAMPs and cell death in TNBC cells. Regorafenib induced the expression of HMGB1 and CRT, and the release of ATP. Regorafenib-induced HMGB1 and CRT were attenuated following STAT3 overexpression. In a 4T1 syngeneic murine model, regorafenib treatment increased HMGB1 and CRT expression in xenografts, and effectively suppressed 4T1 tumor growth. Immunohistochemical staining revealed increased CD4+ and CD8+ tumor-infiltrating T cells in 4T1 xenografts following regorafenib treatment. Regorafenib treatment or programmed death-1 (PD-1) blockade using anti-PD-1 monoclonal antibody reduced lung metastasis of 4T1 cells in immunocompetent mice. While regorafenib increases the proportion of MHC II high expression on dendritic cells in mice with smaller tumors, the combination of regorafenib and PD-1 blockade did not show a synergistic effect on anti-tumor activity. These results suggest that regorafenib induces ICD and suppresses tumor progression in TNBC. It should be carefully evaluated when developing a combination therapy with an anti-PD-1 antibody and a STAT3 inhibitor.

30 September 2022 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
CLChih-Yi Lin
Chih-Yi Lin
CYChung-Jen Yu
Chung-Jen Yu
CSChia-I Shen
Chia-I Shen
CLChun-Yu Liu
Chun-Yu Liu
TCTa-Chung Chao
Ta-Chung Chao
JLJiun-I Lai
Jiun-I Lai

Verified
Journal Article
Open access
PDF file
YTYi-Fang Tsai
Yi-Fang Tsai
CHChi-Cheng Huang
Chi-Cheng Huang
CCChia-Pin Chang
Chia-Pin Chang
CFChin-Jung Feng
Chin-Jung Feng
YLYen-Shu Lin
Yen-Shu Lin
LTLing-Ming Tseng
Ling-Ming Tseng
The aim of this study was to elucidate molecular profiling in HER2-low tumors based on a promising dataset. A total of 615 consecutive HER2-negative breast cancer samples were assayed. The genomic mutations in the two groups with different HER2 expression levels (HER2-0 vs. HER2-low) were compared. The mutation types obtained via next-generation targeted sequencing were correlated with the clinicopathological features of the patients with HER2-0 and HER2-low breast cancer. The results showed that there was a significantly higher percentage of receptor-positive (ER/PR) tumors and more low-level Ki-67 tumors, but a lower incidence of stage I/II tumors in the HER2-low group compared to the HER2-0 group. There was a significantly higher frequency of 17.62% (65/369) for PIK3CA_SNA in the HER2-low group than in the HER2-0 group, which had a frequency of only 9.35% (23/246) (p = 0.006). When the called gene alterations in the triple-negative breast cancer (TNBC) group were compared with those in the luminal-like breast cancer group, there was a significantly high frequency of 28.17% (140/497) for ERBB2_SNA in a luminal-like group than in the TNBC group(16.95% (20/118)).We conclude that the early detection of PIK3CA mutations is likely to be important and might help therapeutic decision making in patients with HER2-low tumors.